PrEP does not lower your immune system. The medications used in PrEP are antiretroviral drugs, not immunosuppressants, and clinical studies in HIV-negative people show no measurable changes in immune cell counts or immune function during use. The concern is understandable, since PrEP uses some of the same drugs that treat HIV, but the way these drugs work has nothing to do with suppressing your body’s defenses.
How PrEP Works Inside Your Cells
PrEP medications belong to a class of drugs that block a specific enzyme HIV needs to copy itself: reverse transcriptase. This enzyme is unique to the virus. Human cells don’t use it. When the active ingredients in PrEP get absorbed into your cells, they sit there waiting. If HIV enters, these drug molecules act as decoys that jam up the virus’s copying machinery, stopping it from establishing an infection.
Because PrEP targets a viral process rather than a human one, it doesn’t interfere with the normal activity of your immune cells. Your white blood cells, antibodies, and other defenses continue working exactly as they would without the medication.
What Studies Show About Immune Cell Counts
Researchers have directly tested whether PrEP changes immune function in HIV-negative people, and the results are reassuring. A study published in The Journal of Infectious Diseases compared T-cell behavior in PrEP users versus people taking a placebo. The percentage of CD4+ T-cells in a state of chronic activation was virtually identical between groups: 1.6% in PrEP recipients versus 1.7% in those on placebo. That difference was not statistically significant.
The same study found that PrEP does not induce changes in CD8+ T-cells, conventional CD4+ T-cells, or regulatory T-cells. In practical terms, the cells responsible for fighting infections, killing virus-infected cells, and regulating your immune response all remained unchanged. The researchers concluded there was no evidence that PrEP alters either the frequency or the strength of immune responses.
Why Early Side Effects Feel Like a Weakened Immune System
Some people starting PrEP experience fatigue, headaches, nausea, or mild stomach upset during the first few weeks. These “start-up” symptoms can feel like you’re getting sick, which is likely why some people wonder if PrEP is weakening their defenses. But these effects are the result of your body adjusting to processing a new medication, not a sign of immune suppression. They typically fade within the first month and don’t reflect any underlying change in how well your immune system functions.
PrEP and STI Rates: A Common Misconception
You may have heard that people on PrEP get more sexually transmitted infections, which could sound like evidence of a weakened immune system. The reality is more straightforward. PrEP users get tested for STIs far more frequently than the general population, often every three months as part of their routine care. This intensive screening catches infections that would otherwise go undiagnosed.
A clinic-based study comparing PrEP users to non-users found nearly identical rates of chlamydia and gonorrhea positivity: 10.93% among PrEP users versus 10.71% among non-users. The small difference was not statistically significant. The study’s authors noted that higher STI diagnoses among PrEP users in other research largely reflect intensified screening rather than any biological increase in susceptibility. PrEP does not make your body more vulnerable to bacterial or viral infections.
What PrEP Can Actually Affect
While PrEP doesn’t compromise your immune system, it does have some real, well-documented effects on other parts of the body. The most studied involve bone density and kidney function, both linked specifically to the tenofovir disoproxil fumarate (TDF) formulation.
Studies in HIV-negative adults have found small but measurable declines in bone mineral density with TDF-based PrEP. Researchers observed increased levels of a bone resorption marker called C-telopeptide, indicating that bone tissue breaks down and rebuilds at a slightly faster rate during TDF use. This effect appears to be driven by increased bone turnover rather than kidney-related damage, and the changes are generally modest.
Kidney function also shows minor shifts. One study found a small but statistically significant decline in a measure of how well the kidneys filter blood. However, the proportion of participants who experienced a clinically meaningful drop of 25% or more was not significantly different between the PrEP and placebo groups. The incidence of more serious kidney tubule problems was also very low: 1.7% in the PrEP group versus 1.3% in placebo, a difference that wasn’t statistically significant.
These are the reasons your provider monitors kidney function periodically while you’re on PrEP. A newer formulation using tenofovir alafenamide (TAF) was developed partly to reduce these bone and kidney effects. An injectable option, given every two months, works through a completely different mechanism and avoids tenofovir-related concerns altogether.
PrEP Is Not an Immunosuppressant
Immunosuppressants are drugs designed to dial down your immune system, prescribed after organ transplants or for autoimmune conditions. PrEP does not fit this category in any way. The CDC classifies PrEP medications as antiretroviral drugs, meaning their sole purpose is to prevent a virus from replicating. They don’t reduce the number or activity of your immune cells, don’t increase your susceptibility to infections, and don’t interfere with your body’s ability to respond to vaccines or fight off illness.
Research into whether long-term PrEP use might subtly shift immune markers like antibody profiles or inflammatory signaling is still ongoing, particularly in mucosal tissues. But based on the clinical data available from large trials in HIV-negative adults, there is no indication that PrEP weakens immune defenses in any meaningful way.